Abstract
Complete surgical resection is the recommended treatment for early-stage NSCLC, followed by adjuvant chemotherapy for patients (pts) with resectable stage II–IIIA and select stage IB disease; however, many pts will experience disease recurrence within five yrs post-surgery. Osimertinib, an EGFR-TKI, is approved as adjuvant therapy for pts with resected stage IB–IIIA EGFR-mutated (EGFRm) NSCLC based on results from the Phase III ADAURA trial. We conducted a global, non-interventional study in pts with resectable NSCLC and EGFR test results available to better understand RW EGFRm frequency, treatment practices and recurrence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
